Washington University

Jun Yoshino

Rajendra S Apte

Hideo Arai

Hisataka Yasuda

Tetsuro Enomoto

Provided herein are methods for determining the severity of glaucoma using expression levels of GDF15. Determining the severity of glaucoma can aid in making treatment decisions.

GDF15 in glaucoma and methods of use thereof

The present disclosure provided methods for determining the severity of glaucoma using the expression levels of GDF15. Determining the severity of glaucoma aids in treatment decisions.

The present disclosure provides for the administration of &#x3b2;-NMN, which increases the secretion of adiponectin. The present disclosure also provides an adiponectin secretion enhancer comprising &#x3b2;-nicotinamide mononucleotide, a pharmaceutically acceptable salt thereof or a solvate thereof, and a dietary supplement containing the aforementioned secretion enhancer, which can be ingested in order to increase the secretion of adiponectin. Also disclosed are methods of treating insulin resistance-related diseases such as of metabolic syndrome, diabetes, hyperlipidemia, fatty liver disease, hypertension, obesity, and arteriosclerosis.

Growing community of inventors

St. Louis, MO, United States of America

Jun Yoshino